We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Week in JAMA |

This Week in JAMA FREE

JAMA. 2005;293(6):651. doi:10.1001/jama.293.6.651.
Text Size: A A A
Published online


Ximelagatran, an oral direct thrombin inhibitor, acts rapidly and predictably and could simplify anticoagulant therapy. Two articles in this issue of JAMA report results from clinical trials assessing the efficacy and safety of ximelagatran compared with standard care in the treatment of deep venous thrombosis (DVT) or in the prevention of stroke in patients with atrial fibrillation. In the DVT treatment trialArticle, patients were randomly assigned to receive fixed-dose ximelagatran, 36 mg twice daily, or to receive standard therapy with low-molecular-weight heparin and adjusted-dose warfarin. In the stroke prevention studyArticle, patients were randomly assigned to fixed-dose ximelagatran or adjusted-dose warfarin. In both studies, ximelagatran was as effective as standard therapy and was associated with comparable low rates of bleeding events but was also associated with increased levels of liver enzymes. In a third article, O’Brien and GageArticle describe their analysis of quality-adjusted survival and cost, comparing treatment with ximelagatran, warfarin, or aspirin for stroke prevention in 70-year-old patients with chronic atrial fibrillation. The authors found that ximelagatran is cost-effective only for patients with a high risk of intracranial hemorrhage or a low quality of life while taking warfarin. In an editorial, GurewichArticle reviews the safety and efficacy data from these and other trials of ximelagatran.


When guns are present in the home, storing them locked and unloaded, with ammunition stored separately and locked, is recommended to reduce youth access to guns. However, whether these measures prevent firearm suicide or unintentional injury in children and adolescents is not clear. Grossman and colleaguesArticle conducted a case-control study of firearm-related unintentional and self-inflicted injuries in youth and measured their association with home firearm storage practices. They found that storing guns locked or unloaded and storing ammunition locked and separately were associated with reductions in risk of suicide and unintentional firearm injury. In an editorial, Cole and JohnsonArticle discuss the importance of persuading families who keep firearms in the home to implement safe storage practices.


Patients with cancer are at increased risk of venous thrombosis, but few studies have addressed factors that identify patients at highest risk. Blom and colleagues assessed risk factors for first deep venous thrombosis or pulmonary embolus in patients 18 to 70 years of age. They found that having a malignancy increased the risk of thrombosis 7-fold. Patients with cancer who were at the highest risk of venous thrombosis had a hematologic malignancy, were diagnosed within the past few months, had distant metastases, and were carriers of factor V Leiden or prothrombin 20210A mutations.

See Article


Perinatal arterial ischemic stroke (PAS) is an important cause of neurologic disabilities in infants, but factors associated with increased risk of PAS are not clear. Lee and colleagues conducted a case-control study to identify maternal and infant characteristics associated with risk of PAS. Among a number of maternal and fetal factors more common in cases than controls, history of infertility, preeclampsia, prolonged rupture of membranes, and chorioamnionitis were independently associated with PAS in multivariate analyses.

See Article


Mental health experts say that psychosocial health services are urgently needed to help tsunami survivors in South Asia cope with psychological trauma that could have an impact for years to come.

See Article


Pathogenesis and treatment of vitiligo.

See Article


Authors are invited to submit manuscripts for the annual JAMA issue on medical education.

See Article


For your patients: Information about vitiligo.

See Article


Theme issues on medical applications of biotechnology coming next week in JAMA and in some of the February Archives Journals.



Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...